Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield
A long-standing U.S. Supreme Court doctrine shielding companies that petition the U.S. Food and Drug Administration from antitrust liability is proving increasingly unhelpful to brand-name drugmakers accused of delaying generic-drug rivals...To view the full article, register now.
Already a subscriber? Click here to view full article